| |
 |
ARTICLES 
|
|
| Needed: qualitative improvement in antisarcoma therapy |
| JH Edmonson |
|
JCO Jul 1 1995: 1531–1533.
[PDF]
|
 |
| Long-term complications of cancer chemotherapy |
| J Pedersen-Bjergaard |
|
JCO Jul 1 1995: 1534–1536.
[PDF]
|
|
|
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first- line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group |
| |
A Santoro, T Tursz, H Mouridsen, J Verweij, W Steward, R Somers, J Buesa, P Casali, D Spooner, and E Rankin |
| |
JCO Jul 1 1995: 1537–1545.
[Abstract]
[PDF]
|
|
|
Cardiac function in Wilms' tumor survivors |
| |
K Sorensen, G Levitt, D Sebag-Montefiore, C Bull, and I Sullivan |
| |
JCO Jul 1 1995: 1546–1556.
[Abstract]
[PDF]
|
|
|
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience |
| |
MS Tallman, R Gray, JM Bennett, D Variakojis, N Robert, WC Wood, JM Rowe, and PH Wiernik |
| |
JCO Jul 1 1995: 1557–1563.
[Abstract]
[PDF]
|
|
|
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer |
| |
B Chevallier, P Chollet, Y Merrouche, H Roche, P Fumoleau, P Kerbrat, JY Genot, P Fargeot, JP Olivier, and C Fizames |
| |
JCO Jul 1 1995: 1564–1571.
[Abstract]
[PDF]
|
|
|
Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression |
| |
SN Birrell, DM Roder, DJ Horsfall, JM Bentel, and WD Tilley |
| |
JCO Jul 1 1995: 1572–1577.
[Abstract]
[PDF]
|
|
|
Contralateral breast cancer: annual incidence and risk parameters |
| |
P Broet, A de la Rochefordiere, SM Scholl, A Fourquet, V Mosseri, JC Durand, P Pouillart, and B Asselain |
| |
JCO Jul 1 1995: 1578–1583.
[Abstract]
[PDF]
|
|
|
Carboplatin reinduction after taxane in patients with platinum- refractory epithelial ovarian cancer |
| |
J Kavanagh, D Tresukosol, C Edwards, R Freedman, C Gonzalez de Leon, A Fishman, R Mante, M Hord, and A Kudelka |
| |
JCO Jul 1 1995: 1584–1588.
[Abstract]
[PDF]
|
|
|
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study |
| |
WP McGuire, WJ Hoskins, MF Brady, HD Homesley, WT Creasman, ML Berman, H Ball, JS Berek, and J Woodward |
| |
JCO Jul 1 1995: 1589–1599.
[Abstract]
[PDF]
|
|
|
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas |
| |
A Le Cesne, E Antoine, M Spielmann, T Le Chevalier, E Brain, C Toussaint, N Janin, L Kayitalire, F Fontaine, and J Genin |
| |
JCO Jul 1 1995: 1600–1608.
[Abstract]
[PDF]
|
|
|
Paclitaxel by 1-hour infusion: an active drug in metastatic non-small- cell lung cancer |
| |
JD Hainsworth, DS Thompson, and FA Greco |
| |
JCO Jul 1 1995: 1609–1614.
[Abstract]
[PDF]
|
|
|
Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study |
| |
AC Wolff, DS Ettinger, D Neuberg, RL Comis, JC Ruckdeschel, PD Bonomi, and DH Johnson |
| |
JCO Jul 1 1995: 1615–1622.
[Abstract]
[PDF]
|
|
|
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer |
| |
E de Campos, J Radford, W Steward, R Milroy, M Dougal, R Swindell, N Testa, and N Thatcher |
| |
JCO Jul 1 1995: 1623–1631.
[Abstract]
[PDF]
|
|
|
Chemoradiotherapy with or without granulocyte-macrophage colony- stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group [published erratum appears in J Clin Oncol 1995 Nov;13(11):2860] |
| |
PA Bunn, Jr, J Crowley, K Kelly, MB Hazuka, K Beasley, C Upchurch, R Livingston, GR Weiss, WJ Hicks, and DR Gandara |
| |
JCO Jul 1 1995: 1632–1641.
[Abstract]
[PDF]
|
|
|
Stereotactic radiosurgery for recurrent malignant gliomas |
| |
WA Hall, HR Djalilian, PW Sperduto, KH Cho, BJ Gerbi, JP Gibbons, M Rohr, and HB Clark |
| |
JCO Jul 1 1995: 1642–1648.
[Abstract]
[PDF]
|
|
|
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study |
| |
JH Schornagel, J Verweij, PH de Mulder, F Cognetti, JB Vermorken, P Cappelaere, JP Armand, J Wildiers, A de Graeff, and M Clavel |
| |
JCO Jul 1 1995: 1649–1655.
[Abstract]
[PDF]
|
|
|
Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey |
| |
M Schneider, MC Etienne, G Milano, A Thyss, J Otto, O Dassonville, H Mobayen, L Saudes, T Guillot, and F Demard |
| |
JCO Jul 1 1995: 1656–1662.
[Abstract]
[PDF]
|
|
|
Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity |
| |
MC Etienne, S Cheradame, JL Fischel, P Formento, O Dassonville, N Renee, M Schneider, A Thyss, F Demard, and G Milano |
| |
JCO Jul 1 1995: 1663–1670.
[Abstract]
[PDF]
|
|
|
Perioperative blood transfusions do not affect disease recurrence of patients undergoing curative resection of colorectal carcinoma: a Mayo/North Central Cancer Treatment Group study |
| |
JH Donohue, S Williams, S Cha, HE Windschitl, TE Witzig, H Nelson, RJ Fitzgibbons, Jr, HS Wieand, and CG Moertel |
| |
JCO Jul 1 1995: 1671–1678.
[Abstract]
[PDF]
|
|
|
Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators |
| |
N Malats, M Porta, JL Pinol, JM Corominas, J Rifa, and FX Real |
| |
JCO Jul 1 1995: 1679–1686.
[Abstract]
[PDF]
|
|
|
Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial |
| |
BH Cohen, PM Zeltzer, JM Boyett, JR Geyer, JC Allen, JL Finlay, P McGuire- Cullen, JM Milstein, LB Rorke, and P Stanley |
| |
JCO Jul 1 1995: 1687–1696.
[Abstract]
[PDF]
|
|
|
Progressive varicella presenting with pain and minimal skin involvement in children with acute lymphoblastic leukemia |
| |
P Rowland, ER Wald, JR Mirro, Jr, E Yunis, VC Albo, MR Wollman, and J Blatt |
| |
JCO Jul 1 1995: 1697–1703.
[Abstract]
[PDF]
|
|
|
Distinct patterns of minimal residual disease associated with graft- versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia |
| |
G Pichert, DC Roy, R Gonin, EP Alyea, R Belanger, M Gyger, C Perreault, Y Bonny, I Lerra, and C Murray |
| |
JCO Jul 1 1995: 1704–1713.
[Abstract]
[PDF]
|
|
|
Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer |
| |
T Demirer, S Rowley, CD Buckner, FR Appelbaum, K Lilleby, R Storb, K Schiffman, and WI Bensinger |
| |
JCO Jul 1 1995: 1714–1719.
[Abstract]
[PDF]
|
|
|
Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site |
| |
A van der Gaast, J Verweij, AS Planting, WC Hop, and G Stoter |
| |
JCO Jul 1 1995: 1720–1725.
[Abstract]
[PDF]
|
|
|
Long-term survival after histologic transformation of low-grade follicular lymphoma |
| |
AR Yuen, OW Kamel, J Halpern, and SJ Horning |
| |
JCO Jul 1 1995: 1726–1733.
[Abstract]
[PDF]
|
|
|
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP |
| |
MA Rodriguez, FC Cabanillas, W Velasquez, FB Hagemeister, P McLaughlin, F Swan, and JE Romaguera |
| |
JCO Jul 1 1995: 1734–1741.
[Abstract]
[PDF]
|
|
|
T-cell-rich B-cell lymphomas: diagnosis and response to therapy of 44 patients |
| |
JP Greer, WR Macon, RE Lamar, SN Wolff, RS Stein, JM Flexner, RD Collins, and JB Cousar |
| |
JCO Jul 1 1995: 1742–1750.
[Abstract]
[PDF]
|
|
|
Large-cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: molecular and in situ analysis of a single neoplastic T-cell clone expressing the identical T-cell receptor |
| |
JT Wolfe, L Chooback, DT Finn, C Jaworsky, AH Rook, and SR Lessin |
| |
JCO Jul 1 1995: 1751–1757.
[Abstract]
[PDF]
|
|
|
Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors |
| |
U Tirelli, D Errante, R Dolcetti, A Gloghini, D Serraino, E Vaccher, S Franceschi, M Boiocchi, and A Carbone |
| |
JCO Jul 1 1995: 1758–1767.
[Abstract]
[PDF]
|
|
|
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion |
| |
LJ van Warmerdam, WW ten Bokkel Huinink, S Rodenhuis, I Koier, BE Davies, H Rosing, RA Maes, and JH Beijnen |
| |
JCO Jul 1 1995: 1768–1776.
[Abstract]
[PDF]
|
|
|
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies |
| |
B Uziely, S Jeffers, R Isacson, K Kutsch, D Wei-Tsao, Z Yehoshua, E Libson, FM Muggia, and A Gabizon |
| |
JCO Jul 1 1995: 1777–1785.
[Abstract]
[PDF]
|
|
|
High-dose intravenous melphalan: a review |
| |
BL Samuels and JD Bitran |
| |
JCO Jul 1 1995: 1786–1799.
[Abstract]
[PDF]
|
|
|
Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review |
| |
JC Byrd, WJ Edenfield, DJ Shields, and NA Dawson |
| |
JCO Jul 1 1995: 1800–1816.
[Abstract]
[PDF]
|
|
| Racial differences in radical prostatectomy |
| O Sartor, D Venable, and J Mata |
|
JCO Jul 1 1995: 1823.
[PDF]
|
|
| "Ifosfamide: should the honeymoon be over?": a two-dimensional question for a three-dimensional problem |
| IW Wainer, J Ducharme, and G Batist |
|
JCO Jul 1 1995: 1824a–1826.
[PDF]
|
|
| Ifosfamide: let's not end the honeymoon too soon |
| AY Chang |
|
JCO Jul 1 1995: 1824b–1826.
[PDF]
|
|
| High-dose ifosfamide, carboplatin, and etoposide with autologous stem- cell support |
| BR Meisenberg |
|
JCO Jul 1 1995: 1826–1827.
[PDF]
|
|
| CA-125: a tumor marker in non-Hodgkin's lymphomas? |
| T Pabst and C Ludwig |
|
JCO Jul 1 1995: 1827–1828.
[PDF]
|
|
| Dose-intensive treatment of acute myelogenous leukemia: improved survival? |
| G Schiller |
|
JCO Jul 1 1995: 1828–1830.
[PDF]
|
|
| New and improved titles |
| GB Weiss |
|
JCO Jul 1 1995: 1829–1830.
[PDF]
|
|
| p53 and angiogenesis |
| G Gasparini |
|
JCO Jul 1 1995: 1830a.
[PDF]
|
|
| Fluorouracil and low-dose leucovorin versus fluorouracil and high-dose leucovorin: what is the real cost? What is the answer? |
| J Brook |
|
JCO Jul 1 1995: 1830b–1831.
[PDF]
|
|
| The American Board of Internal Medicine recertification program: nearing liftoff |
| WG Johanson |
|
JCO Jul 1 1995: 1831–1832.
[PDF]
|
|
